FDA Analysis Addresses ARB Impurity Risk to Patients
January 25th 2019Conducted by the FDA, an analysis follows a series of recalls for some generic versions of the angiotensin II receptor blocker (ARB) medicines containing nitrosamine impurities that do not meet the agency’s safety standards.
Read More
Pursuing Specialty Pharmacy Accreditation
Selecting an accreditation agency should be determined by the local business environment and needs.
Read More
Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial
January 25th 2019Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Read More